RxDoctor Payments Data

Ali Shah, MD

Internal Medicine · Denver, CONPI 1013969104

Payments from drug & device makers

$1,575in general payments, 2019–2025

Across 62 payments — averaging $25.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$239
  • Lilly USA, LLC$218
  • AstraZeneca$139
  • Exact Sciences$138
  • Neurocrine Biosciences, Inc.$128
  • Philips North America LLC$99
  • plus $613 from 16 others

What the payments were for

  • Food & beverage$1,575100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,575 in reported general payments places this provider in the 85th percentile of 1,430 internal medicine providers in Colorado.

See all internal medicine providers in Colorado

Medicare billing

Part B allowed, 2024
$68,834
Medicare patients
109
Services billed
972

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide28$35,314
LinzessLinaclotide12$11,574
XareltoRivaroxaban12$9,713
SymbicortBudesonide/Formoterol Fumarate29$8,071
EliquisApixaban13$7,342
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$2,633
Rosuvastatin Calcium62$2,033
Diclofenac Sodium29$1,706
Albuterol Sulfate HfaAlbuterol Sulfate28$929
Atorvastatin Calcium143$898
Metoprolol Succinate64$809
Ulticare Pen NeedlePen Needle, Diabetic11$712
Tamsulosin Hcl49$684
Duloxetine Hcl29$648
Losartan Potassium106$587

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$218$35,31428 claims
AbbVieLinzess$26$11,57412 claims
AstraZenecaSymbicort$139$8,07129 claims
PfizerEliquis$69$7,34213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,430 internal medicine providers in Colorado.

Other internal medicine in Denver

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →